As part of the Agios deal Servier also took rights to vorasidenib – a dual inhibitor of mutated IDH1 and IDH2 – that is in trials for a hard-to-treat form of brain cancer called glioma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback